Guardant Health, Inc.
About Guardant Health, Inc.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
American Credentials
Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →
Financial summary
- Revenue FY2025
- $982.0M
- Net income
- -$416.3M
- Total assets
- $2.0B
- Market cap
- $16.7B
- Gross margin
- 64.5%
- Operating margin
- -44.5%
- Net margin
- -42.4%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $982.0M
- Cost of revenue
- $349.0M
- Gross profit
- $633.0M
- Operating expenses
- $1.1B
- Operating income
- -$437.2M
- Income tax
- -$1.3M
- Net income
- -$416.3M
- EPS (basic)
- $-3.32
- EPS (diluted)
- $-3.32
Balance sheet
- Total assets
- $2.0B
- Current assets
- $1.5B
- Total liabilities
- $2.1B
- Current liabilities
- $302.7M
- Shareholders’ equity
- -$99.3M
Cash flow
- Operating cash flow
- -$184.8M
- Investing cash flow
- -$627.2M
- Financing cash flow
- $671.1M
- Net cash flow
- -$140.8M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $16.7B
- EPS (diluted)
- $-3.32
- Shares outstanding
- 133.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 4, 2018
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $416.3M in FY2025.
- Revenue grew 163% from FY2021 to FY2025.
- Gross margin of 64.5%, net margin -42.4%.
- Trading 6% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Guardant Health, Inc..
Write a review
News about Guardant Health, Inc.
News & sentiment via Polygon.io
